TY - JOUR
T1 - Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody
AU - Ogata, Hidenori
AU - Zhang, Xu
AU - Yamasaki, Ryo
AU - Fujii, Takayuki
AU - Machida, Akira
AU - Morimoto, Nobutoshi
AU - Kaida, Kenichi
AU - Masuda, Teruaki
AU - Ando, Yukio
AU - Kuwahara, Motoi
AU - Kusunoki, Susumu
AU - nakamura, yuri
AU - Matsushita, Takuya
AU - Isobe, Noriko
AU - Kira, Jun-Ichi
N1 - Funding Information:
This study was supported by AMED under Grant Numbers JP17ek0109115 and JP18ek0109376, and by JSPS KAKENHI Grant Number JP18K15454. X.Z. acknowledges financial support from the China Scholarship Council. The authors thank the patients for their participation, Ms. Kojima and Ms. Noguchi for technical assistance, and K. Takase (Department of Neurology, Iizuka Hospital), H. Kishida (Department of Neurology, Yokohama City University Medical Center), K. Ikezoe (Department of Neurology, Matsuyama Red Cross Hospital), A. Fujii (Department of Neurology, Saiseikai Shiga Hospital), M. Mori‐Yoshimura (Department of Neurology, National Center Hospital of Neurology and Psychiatry), M. Shimizu (Department of Neurology, Osaka University Graduate School of Medicine), Y. Yagi and M. Akaza (Department of Neurology and Neurological Science, Tokyo Medical and Dental University), Y. Mizutani (Department of Neurology, Fujita Health University School of Medicine), S. Ota (Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine), E. Horiuchi (Department of Neurology, National Hospital Organization Sagamihara National Hospital), Y. Shibata (Department of Neurology, National Hospital Organization Asahikawa Medical Center), Y. Takai and Y. Sunami (Department of Neurology, Tokyo Metropolitan Neurological Hospital), K. Unoda (Department of Neurology, Osaka Medical College Hospital), K. Kodama (Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences), M. Kanazawa (Department of Neurology, Niigata University Brain Research Institute of Neurology), K. Matsumoto (Department of Neurology, National Hospital Organization Beppu Medical Center), T. Hirunagi and M. Katsuno (Department of Neurology, Nagoya University Graduate School of Medicine), T. Yoshida (Department of Pediatrics, Kyoto University Graduate School of Medicine), Y. Kanai (Department of Internal Medicine III, Shimane University Faculty of Medicine), Y. Hashimoto (Department of Neurology, Japan Community Health Care Organization Kyushu Hospital), and S. Nagata and M. Watanabe (Departments of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University) for data collection. We also thank Edanz Group ( www.edanzediting.com/ac ) for editing a draft of this manuscript.
Funding Information:
HO received a grant from JSPS KAKENHI (Grant No. 18K15454) and received honoraria from Japan Blood Products Organization and CSL Behring. XZ received financial support from the China Scholarship Council. RY received a grant from JSPS KAKENHI (Grant No. 16K09694). MK received honoraria from Teijin, Nihon Pharmaceutical and Japan Blood Products Organization. SK received grants from Ministry of Health, Labour and Welfare of Japan, the Japan Agency for Medical Research and Development (AMED) and Ministry of Education, Culture, Sports, Science and Technology of Japan, and received consultant fees, speaking fees and/or honoraria from Teijin, Japan Blood Product Organization and Nihon Pharmaceutical. YN received a grant and salary from Mitsubishi Tanabe Pharma, Bayer Yakuhin, Ltd., and Japan Blood Products Organization. TM received speaker honoraria payments from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, and Biogen Japan. NI is supported by a grant from JSPS KAKENHI (Grant No. 18K07529), and received grant support from Mitsubishi Tanabe Pharma, Osoegawa Neurology Clinic, Bayer Yakuhin, Ltd., and Japan Blood Products Organization. JK is supported by grants from JSPS KAKENHI (Grant No. 16H02657), Health and Labour Sciences Research Grants on Intractable Diseases (H29‐Nanchitou (Nan)‐Ippan‐043), and grants from the Japan Agency for Medical Research and Development (AMED) under Grant Number JP17ek0109115 and JP18ek0109376, and received consultant fees, speaking fees and/or honoraria from Novartis Pharma, Mitsubishi Tanabe Pharma, Boehringer Ingelheim, Teijin Pharma, Takeda Pharmaceutical Company, Otsuka Pharmaceutical, Astellas Pharma, Pfizer Japan, and Eisai. TF, AM, NM, KK, TM and YA report no disclosures.
Funding Information:
Funding Information This study was supported by AMED under Grant Numbers JP17ek0109115 and JP18ek0109376, and by JSPS KAKENHI Grant Number JP18K15454. X.Z. acknowledges financial support from the China Scholarship Council. This study was supported by AMED under Grant Numbers JP17ek0109115 and JP18ek0109376, and by JSPS KAKENHI Grant Number JP18K15454. X.Z. acknowledges financial support from the China Scholarship Council. The authors thank the patients for their participation, Ms. Kojima and Ms. Noguchi for technical assistance, and K. Takase (Department of Neurology, Iizuka Hospital), H. Kishida (Department of Neurology, Yokohama City University Medical Center), K. Ikezoe (Department of Neurology, Matsuyama Red Cross Hospital), A. Fujii (Department of Neurology, Saiseikai Shiga Hospital), M. Mori-Yoshimura (Department of Neurology, National Center Hospital of Neurology and Psychiatry), M. Shimizu (Department of Neurology, Osaka University Graduate School of Medicine), Y. Yagi and M. Akaza (Department of Neurology and Neurological Science, Tokyo Medical and Dental University), Y. Mizutani (Department of Neurology, Fujita Health University School of Medicine), S. Ota (Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine), E. Horiuchi (Department of Neurology, National Hospital Organization Sagamihara National Hospital), Y. Shibata (Department of Neurology, National Hospital Organization Asahikawa Medical Center), Y. Takai and Y. Sunami (Department of Neurology, Tokyo Metropolitan Neurological Hospital), K. Unoda (Department of Neurology, Osaka Medical College Hospital), K. Kodama (Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences), M. Kanazawa (Department of Neurology, Niigata University Brain Research Institute of Neurology), K. Matsumoto (Department of Neurology, National Hospital Organization Beppu Medical Center), T. Hirunagi and M. Katsuno (Department of Neurology, Nagoya University Graduate School of Medicine), T. Yoshida (Department of Pediatrics, Kyoto University Graduate School of?Medicine), Y. Kanai (Department of Internal Medicine III, Shimane University Faculty of Medicine), Y. Hashimoto (Department of Neurology, Japan Community Health Care Organization Kyushu Hospital), and S. Nagata and M. Watanabe (Departments of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University) for data collection. We also thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Objective: To characterize the CSF cytokine profile in chronic inflammatory demyelinating polyneuropathy (CIDP) patients with IgG4 anti-neurofascin 155 (NF155) antibodies (NF155+ CIDP) or those lacking anti-NF155 antibodies (NF155− CIDP). Methods: Twenty-eight CSF cytokines/chemokines/growth factors were measured by multiplexed fluorescent immunoassay in 35 patients with NF155+ CIDP, 36 with NF155− CIDP, and 28 with non-inflammatory neurological disease (NIND). Results: CSF CXCL8/IL-8, IL-13, TNF-α, CCL11/eotaxin, CCL2/MCP-1, and IFN-γ were significantly higher, while IL-1β, IL-1ra, and G-CSF were lower, in NF155+ CIDP than in NIND. Compared with NF155− CIDP, CXCL8/IL-8 and IL-13 were significantly higher, and IL-1β, IL-1ra, and IL-6 were lower, in NF155+ CIDP. CXCL8/IL-8, IL-13, CCL11/eotaxin, CXCL10/IP-10, CCL3/MIP-1α, CCL4/MIP-1β, and TNF-α levels were positively correlated with markedly elevated CSF protein, while IL-13, CCL11/eotaxin, and IL-17 levels were positively correlated with increased CSF cell counts. IL-13, CXCL8/IL-8, CCL4/MIP-1β, CCL3/MIP-1α, and CCL5/RANTES were decreased by combined immunotherapies in nine NF155+ CIDP patients examined longitudinally. By contrast, NF155− CIDP had significantly increased IFN-γ compared with NIND, and exhibited positive correlations of IFN-γ, CXCL10/IP-10, and CXCL8/IL-8 with CSF protein. Canonical discriminant analysis of cytokines/chemokines revealed that NF155+ and NF155− CIDP were separable, and that IL-4, IL-10, and IL-13 were the three most significant discriminators. Interpretation: Intrathecal upregulation of type 2 helper T (Th2) cell cytokines is characteristic of IgG4 NF155+ CIDP, while type 1 helper T cell cytokines are increased in CIDP regardless of the presence or absence of anti-NF155 antibodies, suggesting that overproduction of Th2 cell cytokines is unique to NF155+ CIDP.
AB - Objective: To characterize the CSF cytokine profile in chronic inflammatory demyelinating polyneuropathy (CIDP) patients with IgG4 anti-neurofascin 155 (NF155) antibodies (NF155+ CIDP) or those lacking anti-NF155 antibodies (NF155− CIDP). Methods: Twenty-eight CSF cytokines/chemokines/growth factors were measured by multiplexed fluorescent immunoassay in 35 patients with NF155+ CIDP, 36 with NF155− CIDP, and 28 with non-inflammatory neurological disease (NIND). Results: CSF CXCL8/IL-8, IL-13, TNF-α, CCL11/eotaxin, CCL2/MCP-1, and IFN-γ were significantly higher, while IL-1β, IL-1ra, and G-CSF were lower, in NF155+ CIDP than in NIND. Compared with NF155− CIDP, CXCL8/IL-8 and IL-13 were significantly higher, and IL-1β, IL-1ra, and IL-6 were lower, in NF155+ CIDP. CXCL8/IL-8, IL-13, CCL11/eotaxin, CXCL10/IP-10, CCL3/MIP-1α, CCL4/MIP-1β, and TNF-α levels were positively correlated with markedly elevated CSF protein, while IL-13, CCL11/eotaxin, and IL-17 levels were positively correlated with increased CSF cell counts. IL-13, CXCL8/IL-8, CCL4/MIP-1β, CCL3/MIP-1α, and CCL5/RANTES were decreased by combined immunotherapies in nine NF155+ CIDP patients examined longitudinally. By contrast, NF155− CIDP had significantly increased IFN-γ compared with NIND, and exhibited positive correlations of IFN-γ, CXCL10/IP-10, and CXCL8/IL-8 with CSF protein. Canonical discriminant analysis of cytokines/chemokines revealed that NF155+ and NF155− CIDP were separable, and that IL-4, IL-10, and IL-13 were the three most significant discriminators. Interpretation: Intrathecal upregulation of type 2 helper T (Th2) cell cytokines is characteristic of IgG4 NF155+ CIDP, while type 1 helper T cell cytokines are increased in CIDP regardless of the presence or absence of anti-NF155 antibodies, suggesting that overproduction of Th2 cell cytokines is unique to NF155+ CIDP.
UR - http://www.scopus.com/inward/record.url?scp=85074599299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074599299&partnerID=8YFLogxK
U2 - 10.1002/acn3.50931
DO - 10.1002/acn3.50931
M3 - Article
C2 - 31657126
AN - SCOPUS:85074599299
SN - 2328-9503
VL - 6
SP - 2304
EP - 2316
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 11
ER -